1. Introduction

Biotechnology Procurement Accountability refers to the legal, administrative, financial, scientific, and ethical responsibility of governments, hospitals, universities, research institutions, and private companies when purchasing biotechnology-related products and services.

It covers procurement of products and services such as:

Vaccines, biological medicines, and diagnostic kits.

Genomic sequencing systems and genetic testing services.

Laboratory equipment, reagents, and biological research materials.

Gene-therapy products, cell therapies, and biotechnology manufacturing systems.

Genetically modified seeds, biological pesticides, and agricultural biotechnology.

Biotechnology research contracts, clinical-trial services, and biomanufacturing facilities.

The central principle is that biotechnology procurement must be transparent, competitive, scientifically justified, safe, financially responsible, and legally reviewable.

Unlike ordinary procurement, biotechnology purchasing can involve additional risks: uncertain clinical evidence, biosafety hazards, intellectual-property restrictions, sensitive genetic information, complex cold-chain requirements, and products whose long-term effects are not fully established.

There is no single universally applicable law called the Biotechnology Procurement Accountability Act. Instead, accountability arises from public procurement legislation, constitutional and administrative law, competition law, product-safety regulation, biosafety rules, contractual obligations, and applicable international agreements.

This explanation focuses primarily on India, with comparative cases from the United States and other jurisdictions.

2. Meaning and scope

Biotechnology procurement accountability has five interconnected dimensions.

Legal accountability

Procurement authorities must comply with applicable tendering rules, constitutional principles, statutory requirements, and contractual obligations.

Scientific and clinical accountability

Decisions should rely on appropriate evidence of quality, safety, efficacy, performance, and suitability for the intended purpose.

Financial accountability

Buyers must justify expenditure, assess total lifecycle costs, prevent fraud, and establish appropriate audit trails.

Safety and ethical accountability

Procurement must account for biosafety, biological-material handling, patient rights, informed consent where relevant, and privacy protections.

Social accountability

Purchasing decisions should not unfairly exclude suppliers, discriminate against patient groups, or unnecessarily restrict access to essential biological products.

3. Legal framework in India

A. Constitutional principles

Articles 14 and 21 of the Constitution of India are particularly relevant to public biotechnology procurement.

Article 14 — Equality before the law: Public authorities cannot make arbitrary procurement decisions, unfairly favour particular suppliers, or apply tender conditions inconsistently.

Article 21 — Protection of life and personal liberty: Decisions concerning essential medicines, vaccines, diagnostics, and public-health systems may implicate the right to life and health-related protections.

Article 19(1)(g): Relevant where procurement restrictions interfere with lawful business activity, subject to constitutionally permitted restrictions.

Article 14 is especially important when government agencies purchase high-value biotechnology products using public funds. A tender must have a legitimate objective, and its conditions must bear a rational relationship to that objective.

Article 21 does not, however, automatically entitle every supplier or patient to a particular biotechnology product. The legal outcome depends on the facts, applicable legislation, and the nature of the public duty.

B. Public procurement rules

The applicable framework depends on the purchasing institution and source of funds. Relevant instruments may include:

General Financial Rules, 2017, particularly the provisions governing public procurement.

Central or state government procurement policies and tender conditions.

The applicable state financial rules, procurement statutes, and departmental manuals.

Government e-Marketplace (GeM) requirements, where applicable.

The Competition Act, 2002, in cases involving collusion, bid-rigging, or abuse of dominance.

The Prevention of Corruption Act, 1988, where bribery or other covered corrupt conduct is involved.

The Right to Information Act, 2005, subject to applicable exemptions and confidentiality protections.

Not every instrument applies to every buyer. A private hospital, a central government department, a state medical corporation, and a publicly funded university may operate under different procurement obligations.

C. Biotechnology and product regulation

Procurement must also account for the regulatory status of the product being purchased.

These regimes serve different purposes. A competitive tender does not replace a mandatory regulatory approval, and a regulatory approval does not automatically establish that a supplier won a procurement competition fairly.

4. Leading case laws on biotechnology procurement accountability

The following judgments establish principles applicable to biotechnology procurement. Some directly concern pharmaceutical procurement, while others establish general rules governing public tenders and are applied by analogy to biotechnology purchases.

Case 1: Tata Cellular v. Union of India (1994)

Supreme Court of India · (1994) 6 SCC 651

Facts and issue: The case concerned government tendering and the limits of judicial review of administrative decisions in awarding contracts.

Judgment: The Supreme Court explained that judicial review primarily examines the legality and fairness of the decision-making process, rather than substituting the court's commercial or technical judgment for that of the competent authority. It identified arbitrariness, bias, mala fides, and procedural impropriety as important grounds for review.

Indian Kanoon+1

Application to biotechnology procurement:

Suppose a state government invites bids for genomic sequencing equipment and awards the contract to a preferred supplier despite unexplained departures from the published criteria. A competing supplier may challenge the decision if there is evidence of unlawful favouritism or procedural unfairness.

However, a court would not ordinarily replace the scientific committee's genuine technical assessment merely because another machine appears preferable.

Legal principle: Technical discretion is permitted, but it must be exercised lawfully, fairly, and without arbitrariness.

Case 2: Michigan Rubber (India) Ltd. v. State of Karnataka (2012)

Supreme Court of India · (2012) 8 SCC 216

Facts and issue: The dispute concerned prequalification conditions in a government tender for tyres, tubes, and flaps. The petitioner challenged the restrictive tender requirements.

Judgment: The Court recognised that public authorities generally have substantial discretion to prescribe eligibility criteria. Courts may intervene where the conditions are arbitrary, discriminatory, mala fide, or irrational, with the public interest being an important consideration.

VoxJuris+1

Application to biotechnology procurement:

A procurement authority purchasing vaccine-manufacturing equipment may legitimately require validated performance, appropriate regulatory compliance, and demonstrated technical capacity.

It should not, however, impose an unnecessary requirement that only one named manufacturer's proprietary technology can satisfy when equivalent, safe alternatives could meet the genuine operational needs.

Legal principle: Qualification criteria must be justified by the procurement's actual requirements, not designed to favour a predetermined bidder.

Case 3: Rusan Pharma Ltd. v. Union of India (2017)

Delhi High Court · W.P.(C) 5596/2016, decided 30 August 2017

Facts and issue: The dispute arose from a Ministry of Health and Family Welfare/National AIDS Control Organisation procurement of buprenorphine tablets. The petitioner challenged the award to another bidder, including the use of a procurement approach that it alleged was inconsistent with the tender process.

Judgment: The Delhi High Court considered the established principles governing government contracts, fairness, tender compliance, and judicial restraint. The case illustrates that a procurement challenge must be assessed in light of the applicable rules, the actual decision-making process, and the wider public interest.

Indian Kanoon+1

Application to biotechnology procurement:

The case is relevant to purchasing biological medicines, vaccines, and other regulated health products because such purchases may involve urgent public-health needs, supplier eligibility, and continuity of treatment.

An emergency procurement route may be justified where the applicable rules permit it, but urgency should not become a pretext for favouritism or unexplained departures from mandatory requirements.

Legal principle: Public-health procurement requires a balance between procedural fairness and timely access to essential products.

Case 4: Reliance Energy Ltd. v. Maharashtra State Road Development Corporation Ltd. (2007)

Supreme Court of India · (2007) 8 SCC 1

Core principle: Fair competition requires a level playing field and sufficiently clear evaluation criteria.

Application to biotechnology procurement:

If a government laboratory invites bids for DNA-sequencing services, the tender should disclose how it will evaluate accuracy, throughput, turnaround time, data security, warranty, and cost.

Secretly introducing a new technical criterion after bids have been submitted could undermine equal treatment and make the award vulnerable to judicial review.

Legal principle: Tender evaluation should follow predetermined, sufficiently clear criteria that give competing suppliers a fair opportunity.

This principle complements the judicial-review framework in Tata Cellular and Michigan Rubber.

Case 5: Centre for Public Interest Litigation v. Union of India (2012)

Supreme Court of India · (2012) 3 SCC 1

Facts and issue: The case arose from the allocation of 2G spectrum and addressed public-resource allocation, transparency, and the exercise of state power.

Judgment: The Supreme Court examined the constitutional importance of fair and non-arbitrary allocation of valuable public resources.

Application to biotechnology procurement:

Although this was not a biotechnology procurement case, its public-resource principles are relevant when governments allocate substantial funds for vaccine programmes, subsidised biological medicines, public genomic laboratories, or biotechnology research grants.

Authorities should be able to explain why a procurement route was chosen, how competing interests were considered, and whether public resources were managed consistently with applicable law.

Legal principle: Public resources cannot be distributed through arbitrary or legally impermissible decision-making.

Case 6: Air India Ltd. v. Cochin International Airport Ltd. (2000)

Supreme Court of India · (2000) 2 SCC 617

Core principle: Courts generally respect the commercial and administrative discretion of public authorities, but public contracting remains subject to fairness and the prohibition on arbitrary action.

Application to biotechnology procurement:

A procurement authority may choose a more expensive biological product where documented evidence establishes meaningful advantages in reliability, efficacy, storage requirements, or long-term operating costs. Lowest price does not invariably mean best value.

The authority should be able to demonstrate that its choice followed the announced criteria and was made in the public interest.

Legal principle: Value-based procurement is permissible, provided that the evaluation is genuine, defensible, and lawful.

5. How these cases work together

These authorities do not mean that every procurement irregularity automatically invalidates a contract. Courts consider the applicable law, materiality of the defect, evidence of unfairness, public interest, and the appropriate remedy.

6. Core principles of biotechnology procurement accountability

A. Transparency and recordkeeping

Public procurement decisions should be documented from the initial assessment of need through contract completion.

India's Department of Expenditure, in its Manual for Procurement of Goods, Second Edition, 2024, emphasises recording the considerations behind procurement decisions, retaining audit trails, and ensuring that records can be retrieved for scrutiny.

Department of Expenditure+1

For biotechnology, the documentation should include:

The scientific and clinical justification for purchasing the product.

The estimated quantity, budget, and demand assessment.

The tender specifications and evaluation criteria.

The reasons for selecting or rejecting bidders.

Regulatory documentation and product-quality assessments.

Delivery records, inspection results, and payments.

Any complaints, deviations, recalls, or corrective actions.

Example: If a government hospital purchases a large quantity of diagnostic kits, the procurement file should explain why those kits were selected, whether the supplier met applicable requirements, and how the kits' performance and delivery were verified.

B. Scientific quality and safety

The cheapest product is not necessarily the safest or most economical.

Procurement committees should assess the product's suitability against the intended clinical or scientific purpose. Depending on the product, relevant factors include:

Applicable marketing authorisations and manufacturing licences.

Quality-control documentation and batch-release requirements.

Validated performance and supporting clinical evidence.

Storage temperature, shelf life, and transport conditions.

Traceability, product recalls, and post-market safety monitoring.

Compatibility with existing laboratory or manufacturing systems.

Scientific requirements should be proportionate to the risks involved. Procurement must not use technical standards as a disguise for favouritism.

C. Financial accountability and value for money

A defensible procurement decision should consider the total cost of ownership rather than merely the initial purchase price.

For example, an automated laboratory platform may have a lower purchase price but require expensive proprietary reagents, maintenance contracts, and software licences.

The evaluation may therefore consider:

\[ \text{Total lifecycle cost} = \text{Purchase} + \text{Operation} + \text{Maintenance} + \text{Disposal} \]

The precise cost model will depend on the procurement and its contractual terms.

Under Rule 21 of the General Financial Rules, 2017, public expenditure is subject to standards of financial propriety, including economy and compliance with applicable financial rules. The current consolidated rules should be consulted for the relevant procurement.

DEPARTMENT OF Expenditure+1

D. Competition and prevention of corruption

Accountability requires safeguards against:

Bid-rigging and collusion among suppliers.

Bribery or undisclosed conflicts of interest.

Specifications designed to favour one manufacturer.

Improper disclosure of confidential bid information.

Artificially inflated prices or false quality certifications.

Improper splitting of contracts to evade approval requirements.

Where the relevant legal elements are established, the Competition Act, 2002, and Prevention of Corruption Act, 1988, may provide additional remedies or sanctions.

The existence of a single supplier is not itself proof of wrongdoing. Proprietary technology, valid patent rights, compatibility requirements, and genuine emergencies may justify restricted procurement where the applicable rules allow it. The reasons must be properly documented.

7. Allocation of legal responsibility

Accountability is distributed among several participants rather than resting solely with the purchasing officer.

A particular person or organisation is liable only where the relevant statutory duty, contractual obligation, misconduct, negligence, or other legal basis is established.

8. Hypothetical case study: procurement of vaccines

Suppose a state government issues a tender for one million vaccine doses.

Three manufacturers submit bids. Supplier A offers the lowest price, Supplier B provides stronger documented cold-chain support, and Supplier C has the most restrictive proprietary distribution arrangement.

The government awards the contract to Supplier B.

This decision is not automatically unlawful merely because Supplier A offered the lowest price. The legal assessment would depend on the following questions:

Were the cold-chain and reliability criteria disclosed in advance?

Were they relevant to vaccine safety and the actual distribution conditions?

Were all suppliers assessed under the same criteria?

Was Supplier B's additional cost justified by documented evidence?

Were all applicable regulatory approvals and quality requirements satisfied?

Were the reasons for the award recorded and the required financial approvals obtained?

If these conditions are met, the award may be defensible even at a higher price.

If the cold-chain requirement was introduced after the bids were received specifically to exclude Supplier A, the process could raise serious concerns under Article 14 and the principles established in Tata Cellular, Michigan Rubber, and Reliance Energy.

The outcome would depend on the evidence, tender terms, applicable procurement rules, and public interest.

9. Remedies for procurement violations

Depending on the circumstances, a procurement dispute may lead to one or more of the following remedies.

Administrative review: The procuring authority may review an evaluation, investigate a complaint, or reconsider a decision in accordance with applicable rules.

Judicial review: An affected party may seek relief under Article 226 of the Constitution before an appropriate High Court where the legal requirements are satisfied.

Audit and vigilance investigation: Suspected financial irregularities or corruption may be referred to the competent audit or vigilance authorities.

Competition enforcement: Bid-rigging or other conduct prohibited by competition law may be investigated by the Competition Commission of India.

Contractual remedies: Depending on the contract and applicable law, remedies may include damages, termination, recovery of losses, or other relief.

Product-safety action: Defective or non-compliant products may be subject to rejection, recall, regulatory action, or other measures authorised by law.

Courts do not necessarily cancel a contract whenever an irregularity is alleged. They consider the seriousness of the violation, available evidence, public interest, and the suitability of the requested remedy.

10. Practical compliance checklist

A public institution purchasing biotechnology products can use the following checklist as a starting point.

Procurement compliance review

0 of 10

Document the need and estimated quantity.

Verify the applicable procurement route and financial approvals.

Confirm relevant regulatory permissions and product specifications.

Use objective, proportionate, disclosed evaluation criteria.

Record technical assessments, conflicts of interest, and award reasons.

Verify supplier capacity, delivery conditions, and quality documentation.

Maintain batch-level traceability and inspection records where applicable.

Monitor contract performance, payments, complaints, and recalls.

Preserve records for audit and lawful disclosure.

Investigate suspected misconduct and implement corrective measures.

Copy checklistReset

11. Conclusion

Biotechnology Procurement Accountability is best understood as a framework of fair competition, scientific integrity, regulatory compliance, financial discipline, and public responsibility.

In India, its legal foundation includes constitutional equality, public financial rules, applicable biotechnology and medicines legislation, competition law, anti-corruption law, and contract law.

The leading procurement cases establish complementary principles: Tata Cellular governs judicial review of administrative decisions; Michigan Rubber addresses tender conditions and public-authority discretion; Rusan Pharma illustrates the application of tender-law principles to pharmaceutical procurement; and Reliance Energy reinforces fair competition and a level playing field.

The central legal test is not simply whether the government obtained the lowest price. It is whether the procurement decision was made lawfully, transparently, on defensible scientific and financial grounds, and in the public interest.

For further research, the most useful next step would be a case-law analysis focused specifically on Indian vaccine, pharmaceutical, and biotechnology procurement disputes, separating direct precedents from general tender-law authorities.